Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIb study of BGS649 in obese males with hypogonadotropic hypogonadism
2015-005760-42Phase 2Completed
- Sponsor
- Mereo BioPharma
- Start
- Mar 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in hypogonadotropic hypogonadism (HH) and obesity comparing BGS649 dose-ranging arms with Placebo control (2 arms). Primary endpoint: Normalization of total testosterone at Week 24. Started Mar 2016; status: completed.
02
Drugs
leflutrozole
03
Conditions
hypogonadotropic hypogonadism (HH)obesity
Beyond the preview
Go deeper on 2015-005760-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-005760-42.